Vendor, Miami, FL
Cygnos Biotech, LLC
UEI PXYDY5CQJDM3, CAGE 8WQ76
2 awards and $1,601,657 obligated between March 4, 2025 and May 15, 2026, 100% under full and open competition, against 2.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $1,601,657 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| W911SR26CA003Definitive Contract, January 29, 2026, Full and Open Competition After Exclusion of Sources, 1 offers | W6QK ACC-APGDepartment of the Army | The Purpose of This Small Business Innovation Research (Sbir) Phase II Contract Is to Show Efficacy of Anti-Viral Treatment with the PVX TheNAICS 541714, PSC AC12 | $1,397,164 |
| W911SR25C0013Definitive Contract, March 4, 2025, Full and Open Competition After Exclusion of Sources, 4 offers | W6QK ACC-APGDepartment of the Army | Research to Create a Class of Agnostic Drugs Targeting the Host to Assist in Fighting Off a Broad Spectrum of Viral Pathogens.NAICS 541714, PSC AN13 | $204,493 |
- Places of performance
- Florida
- Product and service codes
- AC12 National Defense R&D Services; Department Of Defense - Military; Applied ResearchAN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 4 across 2 awards